by McDermott + Bull | Jan 6, 2022 | Article, Interim Leaders, Mark McConnell, Mark McConnell Article
We recently closed the chapter that was 2021, a second year of dealing with a global pandemic and the uncertainty of the new variants that arose. We saw record stock market runs, enormous transaction activity for PE firms, and an economy that rose and recovered from...
by McDermott + Bull | Dec 13, 2021 | Article, Healthcare + Life Sciences Article, Jake Vander Zanden
Ringing in the New Year As we slowly emerge from the pandemic, we are beginning to see a bright spot in the future of the life sciences industry and wider global economy. From what I can gather, there is a collective and anticipatory sigh of relief that this will all...
by McDermott + Bull | Dec 1, 2021 | Article, Ken Dropiewski
WHO + WHY? Looking back at M+A activity this year, I took notice of a few that stood out, irrespective of their size. Over the past 12 months, companies have experienced an increase in IPOs. However, if this was used as their exit strategy, it means M+A is down....
by McDermott + Bull | Nov 10, 2021 | Article, Brandon Biegenzahn, Financial Services Article
The Demand for Talent To state the obvious, the pandemic has brought about tremendous change across the global landscape. The most glaring impact in my world, brokering in executive level talent in financial services, has been the massive demand for talent, and the...
by McDermott + Bull | Sep 7, 2021 | Article, Ken Dropiewski
THE GREAT RESIGNATION: WHAT THE FUTURE HOLDS FOR TODAY’S JOB MARKET We hear it day in and day out — it’s so hard to find talent in this market! Oftentimes, the concept of finding “the perfect fit” stands in the way of a company making the best hiring decision, and not...
by McDermott + Bull | Aug 3, 2021 | Article, Jake Vander Zanden
TRANSITIONING TO A HYBRID WORKFORCE IN LIFE SCIENCES As we begin to re-enter a normalized version of the past 16 months, the transition from fully remote workforces to new working environments is nearly upon us. I have heard everything from Life Sciences companies...
